Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Following people with myelofibrosis over time in Europe

Observes adults with myelofibrosis across European centres through regular follow-up visits.

Plain-language title generated from the registry record
Registry title: Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

Key facts

Where
Alessandria, Bergamo, Bologna, Catania, Florence, Milan, Monza, Naples, Novara, Pavia, Roma, Torino, Tricase, Verona, and Vicenza, ItalySee the 18 sites

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

Source: NCT06533813, who can take part

Where in Italy

  • A.S.O. SS. Antonio e Biagio e C.Arrigo, SC EmatologiaAlessandria, ItalyTaking people
  • ASST Papa Giovanni XXIII, SC EmatologiaBergamo, ItalyTaking people
  • Policlinico S. Orsola - Malpighi, Unità di EmatologiaBologna, ItalyTaking people
  • Azienda Ospedaliero - Universitaria "Policlinico Vittorio Emanuele" - PO Gaspare Rodolico, Dipartimento di Ematologia con Trapianto di midollo OsseoCatania, ItalyTaking people
  • AOU Careggi di Firenze, Divisione di EmatologiaFlorence, ItalyTaking people
  • ASST Grande Ospedale Metropolitano Niguarda, Divisione di EmatologiaMilan, ItalyTaking people
  • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, EmatologiaMilan, ItalyTaking people
  • Ospedale San Raffaele, Unità Operativa di Ematologia e Trapianto Midollo OsseoMilan, ItalyTaking people
  • Fondazione IRCCS San Gerardo dei TintoriMonza, ItalyTaking people
  • Azienda Ospedaliera Universitaria Federico II, Divisione di EmatologiaNaples, ItalyTaking people
  • Azienda Ospedaliero-Universitaria Maggiore Della Carita, SCDU EmatologiaNovara, ItalyTaking people
  • Fondazione IRCCS Policlinico San Matteo, Divisione di EmatologiaPavia, ItalyTaking people
  • Fondazione Policlinico Universitario A. Gemelli - Università Cattolica del Sacro Cuore, UCSC EmatologiaRoma, ItalyTaking people
  • Policlinico Umberto I, Dipartimento Ematologia, Oncologia e DermatologiaRoma, ItalyTaking people
  • A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette- S.C. Ematologia UTorino, ItalyNot yet recruiting
  • Ospedale Cardinale G. PanicoTricase, ItalyNot yet recruiting
  • Azienda Ospedaliera Universitaria Integrata - Ospedale Borgo Roma, Unità di EmatologiaVerona, ItalyTaking people
  • Azienda ULSS 8 Berica - Ospedale San Bortolo, Divisione di EmatologiaVicenza, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Trial code
NCT06533813
Record updated
9 July 2026
Original description
Multicenter retrospective and prospective European observational study. At each site, all consecutive patients with a 2016- or 2022 World Health Organization (WHO) confirmed diagnosis of myelofibrosis (MF) established from 01/01/2018 to 31/12/2027 will be enrolled into the study. Yearly follow-up updates will be scheduled until the end of data collection on 31/12/2028 or until the last available patient visit, whichever comes first. At least 1 year of follow-up will be ensured from the last patient enrolled.Read full original descriptionShow less

Clinical Epidemiology in Contemporary Patients With Myelofibrosis (ERNEST-3): A European LeukemiaNet (ELN) Observational Study

Multicenter retrospective and prospective European observational study. At each site, all consecutive patients with a 2016- or 2022 World Health Organization (WHO) confirmed diagnosis of myelofibrosis (MF) established from 01/01/2018 to 31/12/2027 will be enrolled into the study. Yearly follow-up updates will be scheduled until the end of data collection on 31/12/2028 or until the last available patient visit, whichever comes first. At least 1 year of follow-up will be ensured from the last patient enrolled.

Inclusion: Diagnosis of primary myelofibrosis (PMF) or secondary (i.e., post-ET/PV MF) myelofibrosis according to 2016- or 2022-WHO criteria ascertained between 01/01/2018 and 31/12/2027; Age ≥ 18 years; Signed informed consent where applicable, in line with current European General Data Protection Regulation (GDPR) directives.

Exclusion: Concurrent participation to interventional clinical trials in MF; Diagnosis of early/prefibrotic primary myelofibrosis.

ClinicalTrials.gov NCT06533813